Comparative Effects of Post-isometric Relaxation and Active Release Technique Patients With Deep Gluteal Syndrome

July 3, 2025 updated by: Riphah International University

Comparative Effects of Post-isometric Relaxation and Active Release Technique in Pain, Range of Motion and Disability in Patients With Deep Gluteal Syndrome

Deep gluteal syndrome included piriformis syndrome. Tight piriformis muscle gives symptoms of Sciatica in patients with Deep Gluteal Syndrome. Two different techniques which will be used to improve deep gluteal syndrome are Active release technique and Post-isometric relaxation. Active release therapy is a set of techniques for treating musculoskeletal problems. After feeling for the precise location of musculoskeletal dysfunction, practitioners aim to release affected tissues. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study will be a randomized controlled trial and will be conducted in Riphah Rehabilitation Clinic Lahore. Non-probability consecutive sampling will be used to collect the data. Sample size of 46 subjects with age group between 35-55 years of both male and female will be taken. Data will be collected from the patients having present complaint of pain in buttock, low back and radiating to leg. Outcome measures will be taken using Numeric Pain Rating Scale (NPRS) for pain, Low Extremity Functional Scale for disability and Universal Goniometer (GU) for Range of Motion. An informed consent will be taken. Subjects will be selected on the basis of inclusion and exclusion criteria and will be equally divided into two groups by random number generator table. Both the Groups will receive hot pack, TENS and ultrasound as well as stretching exercises of piriformis while Group A will receive Post-isometric relaxation and Group B will receive Active release technique. Outcome measures will be measured at baseline and after 4 weeks. Data analysis will be done by SPSS version 21.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
46

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan, 54000
        • Ittefaq Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • •Age group between 35 and 55 years

    • Both gender male and female
    • Having pain and tenderness in gluteal space
    • Gluteal pain radiating through the posterior of thigh and lower limb

Exclusion Criteria:

  • • Pregnancy

    • Malignancies
    • Degenerative spine disorders like lumber spondylosis, canal stenosis, spondylolisthesis, neural compressions due to intervertebral disc lesions
    • Any vertebral or hip fracture.
    • History of spinal surgery, TB spine, osteoarthritis, rheumatoid disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Post- Isometric Relaxation
Post Isometric Relaxation Technique to Piriformis; Lay the patient in the supine position and have the practitioner stand on the same side as the affected piriformis muscle. Bend the knee of the affected side and place the foot of that side on the lateral aspect of the opposite knee. Have the practitioner push knee medially until meeting the restrictive barrier. Have the patient push against the practitioner's resistance for 3 to 5 seconds, allow for a period of isometric relaxation, then engage a new barrier; repeat three times. Return the patient to a neutral position and reassess using supine or prone piriformis testing.
Other: Post- Isometric Relaxation
Post Isometric Relaxation Technique to Piriformis; Lay the patient in the supine position and have the practitioner stand on the same side as the affected piriformis muscle. Bend the knee of the affected side and place the foot of that side on the lateral aspect of the opposite knee. Have the practitioner push knee medially until meeting the restrictive barrier. Have the patient push against the practitioner's resistance for 3 to 5 seconds, allow for a period of isometric relaxation, then engage a new barrier; repeat three times. Return the patient to a neutral position and reassess using supine or prone piriformis testing.
Experimental: Active Release Technique

Active Release Technique:

Patient position is side lying on the sound side. Therapist stands behind the patient. The upper leg must be in flexion on knee and slight extension Now apply pressure with both thumbs on piriformis and ask patient to flex and extend his hip and also external and internal rotation on hip in flexion. The gluteal muscle is taken from a shortened position to a fully lengthened position while the physiotherapist's contact hand holds tension longitudinally along the soft tissue fibers.
Other: Active Release Technique
Patient position is side lying on the sound side. Therapist stands behind the patient. The upper leg must be in flexion on knee and slight extension Now apply pressure with both thumbs on piriformis and ask patient to flex and extend his hip and also external and internal rotation on hip in flexion. The gluteal muscle is taken from a shortened position to a fully lengthened position while the physiotherapist's contact hand holds tension longitudinally along the soft tissue fibers.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Numerical Pain Rating Scale (NPRS)
Time Frame: upto 4 weeks
Patient level of pain will be assessed using this scale. This scale ranges from 0 to 10. 0 indicates "no pain" and 10 indicated "worst pain".
upto 4 weeks
Universal Goniometer (UG)
Time Frame: upto 4 weeks
The range of motion will be measured using universal goniometer. A universal goniometer has 3 parts, which include the following: A body is designed like a protractor and may form a full or half-circle. It has a scale for the measurement of the angle. The scale can extend from 0 to 180 degrees for half-circle models or 0 to 360 degrees for full-circle models.
upto 4 weeks
Lower Extremity Functional Scale (LEFS)
Time Frame: upto 4 weeks
The Lower Extremity Functional Scale (LEFS) is a questionnaire containing 20 questions about a person's ability to perform everyday tasks. The LEFS can be used by clinicians as a measure of patients' initial function, ongoing progress and outcome, as well as to set functional goals.
upto 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Samrood Akram, PhD*, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 3, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 14, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 14, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR &AHS/24/0161 Ujala

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings